John McCamant really has his fingers on the pulse of the Bio-tech industry (poor pun intended). GenVek (Nasdaq:GNVC) caught his eye with a gene based treatment for inoperable pancreatic cancer. He believes that the phase III trial will be set up soon, and he has a BUY on this stock under $3 (currently sells at $2.44). Amylin Pharma (Nasdaq:AMLN) is developing a once a week diabetes treatment which could give the stock a nice push.
Bio-tech is a tough industry to figure out, so leave it to the pros. LISTEN IN!
http://www.wallstreetreporter.com/page.php?page=featured&id=27350
Subscribe to:
Post Comments (Atom)
2 comments:
Thanks for writing this.
Nice take on newsletter.
Post a Comment